You are here: HomeNewsHealth2020 03 09Article 889240

Health News of Monday, 9 March 2020

Source: classfmonline.com

Test COA FS, COA injectable as cure for Coronavirus – Center to Noguchi

File photo File photo

The Center of Awareness Global Peace Mission has called on the government and the Noguchi Memorial Institute of Medical Research to conduct further research into an organic antiviral medicine COA FS and COA injectable it has discovered to battle coronavirus after the World Health Organisation (WHO) declared the life-threatening disease an epidemic.

According to the Executive President of the Center of Awareness Global Peace Mission, Prof. Samuel Ato Duncan, the centre has developed an organic antiviral medicine known as COA products that boost immune system and naturally fights viruses.

With the world recording rising cases and deaths from coronavirus, Prof Duncan is appealing to the government and Noguchi to do further clinical trials into the organic medicine product, which he believes can be a solution to curing coronavirus.

Speaking to Class News’ Jerry Akornor on the sidelines of a press conference in Accra on Monday, 9 March 2020, Prof Duncan said coronavirus poses a serious threat to the human race.

He, however, noted that despite the threat, there is hope as his center has exported 15 boxes of COA FS and COA injectable to China for treatment of coronavirus patients and the results have been positive.

"We sent 15 boxes of the COA products to China two weeks ago to try coronavirus patients and information reaching us indicate that there have been significant improvement in their conditions," he stated.

Meanwhile, African Union as part of its joint continental strategy has set up Africa Task Force for Coronavirus (AFTCOR) to collaborate for preparedness and response with focus on six technical areas which include:

1. Surveillance including screening at points-of-entry

2. Infection prevention and control in healthcare facilities.

3. Clinical management of persons with severe COVID-19 infection.

4. Laboratory diagnosis and subtyping.

5. Risk communications

6. Supply chain and stockpiling medical commodities.